Skip to main content
. 2019 Apr 6;8(4):321. doi: 10.3390/cells8040321

Table 1.

Cyclin-Dependent Kinases (CDK)4/6 inhibitors’ toxicity profiles.

Palbociclib Ribociclib Abemaciclib
Monotherapy [46] +letrozole PALOMA-2 [47] +fulvestrant PALOMA-3 [48] Monotherapy [49] +letrozole MONALEESA-2 [43] +fulvestrant MONALEESA-3 [50] Monotherapy MONARCH-1 [44] +fulvestrant MONARCH-2 [45] +letrozole/anastrozole MONARCH-3 [51]
Adverse Event (any grade) Neutropenia (92%) Neutropenia (80%) Neutropenia (80%) Neutropenia (46%) Neutropenia (75%) Neutropenia (70%) Neutropenia (85%) Neutropenia (46%) Neutropenia (41%)
Leukopenia (100%) Leukopenia (40%) Leukopenia (50%) Leukopenia (43%) Leukopenia (33%) Nausea (45%) Leukopenia (90%) Diarrhea (86%) Diarrhea (81%)
Thrombocytopenia (76%) Nausea (35%) Infections (42%) Thrombocytopenia (30%) Nausea (50%) Fatigue (32%) Thrombocytopenia (76%) Nausea (45%) Nausea (39%)
Anemia (70%) Fatigue (35%) Fatigue (40%) Fatigue (45%) Infections (50%) Diarrhea (29%) Anemia (69%) Fatigue (40%) Fatigue (40%)
Lymphopenia (65%) Arthralgia (33%) Nausea (32%) Nausea (42%) Fatigue (37%) Leukopenia (28%) Diarrhea (90%) Abdominal pain (35%) Infections (39%)
Alopecia (33%) Diarrhea (35%) Vomiting (27%) Fatigue (65%)
Alopecia (33%) Constipation (25%) Nausea (65%)
Arthralgia (24%) Decreased appetite (45%)
Cough (22%) Abdominal pain (40%)
Headache (22%) Vomiting (35%)
Alopecia (19%)
Rash (18%)
Anemia (17%)
Adverse Event (grade 3–4) Neutropenia (54%) Neutropenia (66%) Neutropenia (65%) Neutropenia (27%) Neutropenia (59%) Neutropenia (53%) Neutropenia (27%) Neutropenia (24%) Neutropenia (21%)
Leukopenia (51%) Leukopenia (25%) Leukopenia (28%) Leukopenia (17%) Leukopenia (21%) Leukopenia (14%) Leukopenia (28%)
Lymphopenia (30%) Fatigue (2%) Anemia (3%) Diarrhea (20%)
Nausea (2%) Fatigue (2%)
Back Pain (2%)
Nausea (1%)
Constipation (1%)
Headache (1%)